Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research, 2020 FCA 30
| Jurisdiction | Federal Jurisdiction (Canada) |
| Court | Court of Appeal (Canada) |
| Citation | 2020 FCA 30 |
| Date | 30 January 2020 |
-
- This document is available in original version only for vLex customers
View this document and try vLex for 7 days - TRY VLEX
- This document is available in original version only for vLex customers
67 practice notes
-
Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
...this hypothetical person does not benefit from inventiveness (Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2020 FCA 30 [Hospira] at para 79, citing Beloit Canada Ltd. v Valmet Oy, [1986] FCJ No. 87, 8 CPR (3d) 289 (FCA) [Beloit] at 294). It is worth repeating th......
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...therapy with Inflectra and MTX. [63] While the admissibility of the IMS data in Hospira FC was challenged on appeal (reported at 2020 FCA 30 [Hospira FCA]), the Federal Court of Appeal [FCA] found it unnecessary to address the hearsay argument based on the additional evidence that already s......
-
Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
...the claim as written and understood” (at paras 32–34). [165] In Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2020 FCA 30, [Hospira FCA] the FCA also saw no error in the Federal Court judge’s decision to interpret the words of the claims to have their plain meani......
-
Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
...the claim as written and understood” (at paras 32–34). [110] In Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2020 FCA 30, [Hospira FCA] the FCA also saw no error in the Federal Court judge’s decision to interpret the words of the claims to have their plain meani......
Request a trial to view additional results
53 cases
-
Angelcare Canada Inc. v. Munchkin, Inc., 2022 FC 507
...this hypothetical person does not benefit from inventiveness (Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2020 FCA 30 [Hospira] at para 79, citing Beloit Canada Ltd. v Valmet Oy, [1986] FCJ No. 87, 8 CPR (3d) 289 (FCA) [Beloit] at 294). It is worth repeating th......
-
Takeda Canada Inc. v. Apotex Inc., 2024 FC 106
...therapy with Inflectra and MTX. [63] While the admissibility of the IMS data in Hospira FC was challenged on appeal (reported at 2020 FCA 30 [Hospira FCA]), the Federal Court of Appeal [FCA] found it unnecessary to address the hearsay argument based on the additional evidence that already s......
-
Eli Lilly Canada Inc. v. Mylan Pharmaceuticals ULC, 2020 FC 816
...the claim as written and understood” (at paras 32–34). [165] In Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2020 FCA 30, [Hospira FCA] the FCA also saw no error in the Federal Court judge’s decision to interpret the words of the claims to have their plain meani......
-
Eli Lilly Canada Inc. v. Apotex Inc., 2020 FC 814
...the claim as written and understood” (at paras 32–34). [110] In Hospira Healthcare Corporation v Kennedy Trust for Rheumatology Research, 2020 FCA 30, [Hospira FCA] the FCA also saw no error in the Federal Court judge’s decision to interpret the words of the claims to have their plain meani......
Request a trial to view additional results
13 firm's commentaries
-
IP Litigation 2020 Year In Review
...Apotex Inc. et al, 2021 FC 7 at para. 223 (Justice Phelan). 33. Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research, 2020 FCA 30 (Nadon, Rivoalen, Locke JJA.). 34. Biogen Canada Inc et al v. Taro Pharmaceuticals Inc; Pharmascience Inc., 2020 FC 621. 35. Amgen Inc. v. P......
-
How Well Does Canadian Law Protect Information Products? The Case Of Patents Over Diagnostic Methods
...Company v. BNSF Railway Company, 2018 FC 614, at para 46; Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research, 2020 FCA 30, at para 15 Eli Lilly & Co v Apotex Inc, 2010 FCA 240, aff'g 2009 FC 991. See Monsanto Canada Inc. v. Schmeiser, 2004 SCC 34, at paras 35 and 44. ......
-
How Well Does Canadian Law Protect Information Products? The Case Of Patents Over Diagnostic Methods
...Company v. BNSF Railway Company, 2018 FC 614, at para 46; Hospira Healthcare Corporation v. Kennedy Trust for Rheumatology Research, 2020 FCA 30, at para 15 Eli Lilly & Co v Apotex Inc, 2010 FCA 240, aff'g 2009 FC 991. See Monsanto Canada Inc. v. Schmeiser, 2004 SCC 34, at paras 35 and 44. ......
-
Patentability In Canada: Federal Court Of Appeal Questions The Fixed Dosage Amount vs Dosage Range Distinction
...v Canada, 2014 FC 1251 4 e.g. Novartis Pharmaceuticals v Cobalt, 2013 FC 985; Janssen v Mylan Pharmaceuticals, 2010 FC 1123 5 2020 FCA 30, on appeal as relating to patent validity from 2018 FC 259 6 [1974] SCR 111 7 2018 FC 259 at paras 136-155, quote from para 147 [Remicade/Inflectra Trial......
Request a trial to view additional results